# A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects

> **NCT02386436** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 41 (actual)

## Conditions studied

- Scleroderma, Systemic

## Interventions

- **DRUG:** GSK2330811
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02386436
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-21
- **Primary completion:** 2016-04-11
- **Final completion:** 2016-04-11
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02386436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02386436, "A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02386436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*